Perianal Adenoma

Perianal adenoma, also known as hepatoid gland adenoma or circumanal gland adenoma, is a benign neoplasm arising from the modified sebaceous (hepatoid) glands located in the perianal region of dogs. These glands are androgen-dependent and are normally present in the skin around the anus, prepuce, tail, and hindlimbs. Perianal adenomas are the most common perianal tumors in dogs, accounting for approximately 80% of all perianal neoplasms. They typically present as slow-growing, well-circumscribed, firm to rubbery masses in the perianal area, often in intact male dogs. Although benign, they can cause significant clinical signs due to their size, location, and potential for ulceration, infection, or interference with defecation. Surgical excision is the treatment of choice, with a low recurrence rate if complete excision is achieved. In some cases, hormonal manipulation (castration) is recommended to reduce the stimulus for tumor growth, especially in intact males. The disease is rare in cats, and when it occurs, it is often malignant (perianal adenocarcinoma).

The primary etiology of perianal adenoma is the influence of androgens on the hepatoid glands. These glands are androgen-dependent, and their proliferation is stimulated by testosterone. In intact male dogs, high circulating testosterone levels promote the development of these tumors. Castration removes the source of testosterone, leading to regression of existing tumors and prevention of new tumor formation. Other potential contributing factors include genetic predisposition, as certain breeds (e.g., Siberian Huskies, Cocker Spaniels, Beagles) are overrepresented. Chronic inflammation or irritation of the perianal area may also play a role, although this is not well established. There is no evidence of a viral or infectious etiology. In females, perianal adenomas are rare and are typically associated with ovarian hormone imbalances or the use of exogenous hormones. The exact cellular mechanisms involve androgen receptor activation leading to cell proliferation and inhibition of apoptosis in hepatoid gland cells.

Perianal adenoma is predominantly a disease of dogs, with a strong predilection for intact male dogs. The median age at presentation is 10 years, with a range of 1 to 18 years. Breeds reported to be at higher risk include Siberian Huskies, Cocker Spaniels, Beagles, Samoyeds, and Bulldogs. Mixed-breed dogs are also commonly affected. Intact male dogs have a significantly higher incidence compared to neutered males and females. In females, the tumor is rare and often associated with hyperestrogenism or the use of progestin compounds. The incidence in cats is extremely low, and when perianal tumors occur in cats, they are more likely to be malignant (perianal adenocarcinoma). The tumor is more common in older animals, reflecting the cumulative exposure to androgens over time. There is no known geographic or environmental predilection.

Perianal adenomas arise from the hepatoid glands, which are modified sebaceous glands located in the perianal dermis. These glands are under the influence of androgens, which bind to androgen receptors on glandular cells, promoting cell proliferation and glandular hyperplasia. Over time, this hyperplasia can progress to a benign neoplasm (adenoma). The tumor is typically well-circumscribed, encapsulated, and slow-growing. Histologically, it is composed of nests and cords of large polyhedral cells with abundant eosinophilic cytoplasm, resembling hepatocytes, hence the name 'hepatoid'. The tumor may be solitary or multiple. As the tumor grows, it can cause mechanical obstruction of the anal canal, leading to tenesmus, dyschezia, and constipation. Ulceration and secondary bacterial infection can occur due to trauma from feces or licking. Although benign, the tumor can be locally invasive if it becomes large, but metastasis is extremely rare. In contrast, perianal adenocarcinoma is malignant and can metastasize to regional lymph nodes and distant organs.

The most significant predisposing factor is intact male status, due to the androgen dependence of the hepatoid glands. Age is also a factor, with older dogs being more commonly affected. Breed predisposition suggests a genetic component, with certain breeds having a higher incidence. Hormonal imbalances, such as hyperestrogenism in females or the use of exogenous hormones, can also predispose to tumor development. Chronic perianal irritation or inflammation may contribute, although this is not well documented. Obesity and poor perianal hygiene may increase the risk of secondary complications but are not direct causes. Neutering at a young age significantly reduces the risk of developing perianal adenomas.

Clinical signs of perianal adenoma are primarily related to the presence of a mass in the perianal region. The mass is typically firm, well-circumscribed, and may be single or multiple. It can vary in size from a few millimeters to several centimeters in diameter. The overlying skin may be normal, ulcerated, or alopecic. Dogs may exhibit licking or biting at the area, leading to self-trauma and secondary infection. Larger masses can cause tenesmus, dyschezia, constipation, and fecal incontinence. In some cases, the mass may bleed, especially if ulcerated. On digital rectal examination, the mass is palpable and may be attached to the surrounding skin or deeper tissues. Systemic signs are uncommon unless the tumor is malignant and has metastasized. In advanced cases, there may be perianal swelling, pain, and discharge.

Differential diagnoses for perianal adenoma include: 1) Perianal adenocarcinoma: Malignant counterpart, more common in females and neutered males, often larger, more invasive, and may metastasize. Histopathology is essential for differentiation. 2) Anal sac adenocarcinoma: Arises from the anal sacs, often associated with hypercalcemia, and may be bilateral. 3) Perianal gland hyperplasia: Non-neoplastic proliferation of hepatoid glands, often in intact males, may regress after castration. 4) Lipoma: Benign fatty tumor, soft and mobile, may occur in the perianal area. 5) Sebaceous adenoma: Benign tumor of sebaceous glands, similar appearance but different histogenesis. 6) Mast cell tumor: Can occur in the perianal region, may be ulcerated, and requires cytology/histopathology for diagnosis. 7) Squamous cell carcinoma: Malignant tumor of epidermal origin, may be ulcerated and invasive. 8) Fibrosarcoma: Malignant mesenchymal tumor, firm and invasive. 9) Perianal fistula: Chronic inflammatory condition, not a neoplasm, but can present with perianal masses and discharge. 10) Anal sac impaction or infection: May cause perianal swelling and pain. Definitive diagnosis requires fine-needle aspiration or biopsy.

The diagnostic workup for a suspected perianal adenoma begins with a thorough history and physical examination, including digital rectal examination to assess the mass and regional lymph nodes. Fine-needle aspiration (FNA) of the mass is a minimally invasive and highly diagnostic technique. Cytology typically reveals clusters of large polyhedral cells with abundant eosinophilic cytoplasm, consistent with hepatoid cells. If FNA is inconclusive, a biopsy (incisional or excisional) is recommended for histopathological confirmation. Preoperative staging is important to rule out malignancy and metastasis. This includes thoracic radiographs (three views) to evaluate for pulmonary metastases, abdominal ultrasound to assess regional lymph nodes and other organs, and complete blood count, serum biochemistry, and urinalysis. If the tumor is large, invasive, or in a female or neutered male, a more aggressive workup is warranted, including advanced imaging (CT or MRI) to assess local invasion and lymph node involvement. Surgical excision is both diagnostic and therapeutic, and histopathology of the excised tissue provides a definitive diagnosis and assessment of surgical margins.

Laboratory findings in perianal adenoma are typically unremarkable. Complete blood count may show mild neutrophilia if there is secondary infection or inflammation. Serum biochemistry is usually within normal limits, but in cases of anal sac adenocarcinoma, hypercalcemia may be present. Urinalysis is generally normal. Coagulation panel (PT/aPTT) is recommended if surgical intervention is planned, especially in older dogs. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated in cases with significant inflammation or necrosis. If the tumor is malignant, lymph node aspiration may reveal metastatic cells. Overall, laboratory findings are non-specific and primarily used to assess the patient's overall health and surgical risk.

Imaging plays a limited role in the diagnosis of perianal adenoma, but it is useful for staging and surgical planning. Thoracic radiographs (three views) are recommended to rule out pulmonary metastases, especially if malignancy is suspected. Abdominal ultrasound can evaluate the sublumbar lymph nodes and other abdominal organs for metastasis. In cases of large or invasive tumors, computed tomography (CT) or magnetic resonance imaging (MRI) may be used to assess the extent of local invasion, involvement of the anal sphincter, and regional lymphadenopathy. CT provides excellent bony detail and is useful for surgical planning. MRI offers superior soft tissue contrast and can delineate the tumor from surrounding structures. Contrast-enhanced imaging can help identify vascular invasion. However, for most perianal adenomas, imaging is not necessary for diagnosis, and surgical excision is performed based on clinical findings.

Fine-needle aspiration cytology of perianal adenoma typically yields highly cellular smears with clusters of large, polyhedral cells with abundant, granular, eosinophilic cytoplasm and centrally located nuclei. These cells resemble hepatocytes, hence the term 'hepatoid cells'. The cells are uniform and lack features of malignancy such as anisocytosis, anisokaryosis, and prominent nucleoli. Histopathology of excised tissue reveals a well-circumscribed, encapsulated mass composed of nests, cords, and lobules of hepatoid cells supported by a fibrovascular stroma. The cells are large, polyhedral, with abundant eosinophilic cytoplasm and small, uniform nuclei. Mitotic figures are rare. Surgical margins should be evaluated for completeness of excision. In contrast, perianal adenocarcinoma shows cellular atypia, increased mitotic activity, and invasion into surrounding tissues. Special stains, such as immunohistochemistry for cytokeratin and androgen receptors, may be used to confirm the diagnosis and differentiate from other tumors.

The treatment of choice for perianal adenoma is surgical excision. For small, pedunculated masses, simple excision with a scalpel or electrocautery is sufficient. For larger or sessile masses, a more extensive excision may be required, with careful dissection to preserve the anal sphincter. The surgical approach involves a circumferential incision around the mass, with blunt and sharp dissection to remove the tumor with a margin of normal tissue. Hemostasis is achieved with electrocautery or ligation of vessels. The subcutaneous tissue and skin are closed in layers using absorbable suture material (e.g., polydioxanone, polyglactin 910) in a simple interrupted or continuous pattern. In cases where the mass is large and involves the anal sphincter, a partial or complete anal sacculectomy may be necessary. Postoperative management includes pain control, antibiotics if infection is present, and Elizabethan collar to prevent self-trauma. Castration is recommended for intact male dogs to reduce the risk of recurrence and to promote regression of any residual microscopic disease. In cases where surgery is not feasible or the tumor is inoperable, hormonal therapy (e.g., anti-androgens) may be considered, but surgery remains the gold standard. Radiation therapy may be used for incompletely excised tumors or for malignant tumors, but it is rarely needed for benign adenomas.

The prognosis for perianal adenoma is excellent with complete surgical excision. The recurrence rate is low (less than 10%) if the tumor is completely removed and the dog is castrated. In intact males, the recurrence rate is higher (up to 30%) if castration is not performed. The tumor is benign and does not metastasize. However, if the tumor is incompletely excised, it may regrow locally. The prognosis for perianal adenocarcinoma is guarded, with a high rate of metastasis and a median survival time of 12-18 months with aggressive treatment. Negative prognostic indicators for perianal tumors include malignant histology, large size, invasion into surrounding tissues, and metastasis at the time of diagnosis.

Postoperative follow-up for perianal adenoma includes suture removal 10-14 days after surgery. The surgical site should be monitored for signs of infection, dehiscence, or recurrence. The dog should be restricted from excessive activity and licking of the area for 2 weeks. Castration is recommended at the time of surgery or shortly thereafter. Recheck examinations are recommended at 1, 3, 6, and 12 months postoperatively to monitor for recurrence. In cases of malignant tumors, more frequent monitoring, including thoracic radiographs and abdominal ultrasound, is recommended every 3-6 months. Long-term follow-up is generally not required for benign adenomas, but owners should be educated to monitor for new masses.

Clinical pearls: 1) Always perform a digital rectal examination to assess the mass and regional lymph nodes. 2) Fine-needle aspiration is a quick and reliable diagnostic tool. 3) Castration is an essential part of treatment in intact males to prevent recurrence. 4) Use a surgical approach that preserves the anal sphincter to maintain fecal continence. 5) Submit all excised masses for histopathology to confirm the diagnosis and rule out malignancy. Pitfalls: 1) Incomplete excision due to inadequate margins, leading to recurrence. 2) Damage to the anal sphincter during surgery, causing fecal incontinence. 3) Failure to recommend castration, resulting in a higher recurrence rate. 4) Misdiagnosis of a malignant tumor as benign, leading to inadequate treatment. 5) Overlooking the possibility of multiple tumors, which may require multiple excisions.

Perioperative antimicrobial prophylaxis: Cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative antibiotics are not routinely indicated unless there is contamination or infection. Analgesia: Preoperative opioid (e.g., hydromorphone 0.05-0.1 mg/kg IV or IM, or methadone 0.1-0.3 mg/kg IV or IM) and a non-steroidal anti-inflammatory drug (NSAID) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) for 3-5 days postoperatively. Local anesthesia: A lumbosacral epidural with bupivacaine (0.5-1 mg/kg) and morphine (0.1 mg/kg) can provide excellent intraoperative and postoperative analgesia. For pain management, a constant rate infusion (CRI) of fentanyl (2-5 mcg/kg/hr) or lidocaine (25-50 mcg/kg/min) may be used intraoperatively. Postoperative pain can be managed with tramadol (2-5 mg/kg PO q8-12h) if needed. For hormonal therapy in inoperable cases, anti-androgens such as finasteride (0.1-0.5 mg/kg PO q24h) or flutamide (5 mg/kg PO q24h) may be considered, but their efficacy is variable. Always adjust dosages based on renal and hepatic function.

Several studies have evaluated the clinical features and treatment outcomes of perianal adenomas. A retrospective study by Wilson and Hayes (1979) reported that perianal adenomas are the most common perianal tumors in dogs, with a strong male predisposition. Another study by Goldschmidt and Shofer (1992) found that castration significantly reduces the risk of recurrence. A more recent study by Vail et al. (1990) evaluated the efficacy of surgical excision and castration, reporting a recurrence rate of less than 10% when both were performed. The role of hormonal therapy has been investigated, but surgery remains the standard of care. The ACVS consensus statement on perianal tumors recommends surgical excision with histopathological evaluation and castration for intact males. There is limited evidence for the use of radiation therapy in benign adenomas, but it may be considered for incompletely excised tumors. Overall, the literature supports surgical excision as the definitive treatment, with an excellent prognosis for benign adenomas.